WallStSmart

Merck & Company Inc (MRK)vsPerrigo Company PLC (PRGO)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Merck & Company Inc generates 1506% more annual revenue ($66.57B vs $4.14B). MRK leads profitability with a 4.8% profit margin vs -41.8%. PRGO appears more attractively valued with a PEG of 1.14. PRGO earns a higher WallStSmart Score of 45/100 (D+).

MRK

Hold

36

out of 100

Grade: F

Growth: 4.0Profit: 4.5Value: 2.0Quality: 5.0
Piotroski: 3/9Altman Z: 2.27

PRGO

Hold

45

out of 100

Grade: D+

Growth: 2.0Profit: 3.0Value: 7.0Quality: 4.5
Piotroski: 3/9Altman Z: 0.02
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

MRKSignificantly Overvalued (-73.7%)

Margin of Safety

-73.7%

Fair Value

$82.84

Current Price

$143.93

$61.09 premium

UndervaluedFair: $82.84Overvalued
PRGOUndervalued (+74.4%)

Margin of Safety

+74.4%

Fair Value

$57.12

Current Price

$13.66

$43.46 discount

UndervaluedFair: $57.12Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

MRK2 strengths · Avg: 9.0/10
Market CapQuality
$355.10B10/10

Mega-cap, among the largest globally

Free Cash FlowQuality
$4.48B8/10

Generating 4.5B in free cash flow

PRGO1 strengths · Avg: 10.0/10
Price/BookValuation
0.8x10/10

Reasonable price relative to book value

Areas to Watch

MRK4 concerns · Avg: 3.3/10
Price/BookValuation
8.5x4/10

Trading at 8.5x book value

Return on EquityProfitability
7.6%3/10

ROE of 7.6% — below average capital efficiency

Profit MarginProfitability
4.8%3/10

4.8% margin — thin

Debt/EquityHealth
1.293/10

Elevated debt levels

PRGO4 concerns · Avg: 3.0/10
Market CapQuality
$1.98B3/10

Smaller company, higher risk/reward

Operating MarginProfitability
3.8%3/10

Operating margin of 3.8%

Debt/EquityHealth
1.313/10

Elevated debt levels

Piotroski F-ScoreQuality
3/93/10

Weak financial health signals

Comparative Analysis Report

WallStSmart Research

Bull Case : MRK

The strongest argument for MRK centers on Market Cap, Free Cash Flow.

Bull Case : PRGO

The strongest argument for PRGO centers on Price/Book. PEG of 1.14 suggests the stock is reasonably priced for its growth.

Bear Case : MRK

The primary concerns for MRK are Price/Book, Return on Equity, Profit Margin. A P/E of 116.1x leaves little room for execution misses. Thin 4.8% margins leave little buffer for downturns.

Bear Case : PRGO

The primary concerns for PRGO are Market Cap, Operating Margin, Debt/Equity.

Key Dynamics to Monitor

MRK profiles as a value stock while PRGO is a turnaround play — different risk/reward profiles.

PRGO carries more volatility with a beta of 0.60 — expect wider price swings.

MRK is growing revenue faster at 5.1% — sustainability is the question.

MRK generates stronger free cash flow (4.5B), providing more financial flexibility.

Bottom Line

PRGO scores higher overall (45/100 vs 36/100). Both earn "Hold" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Merck & Company Inc

HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA

Merck & Co. is an American multinational pharmaceutical company headquartered in Kenilworth, New Jersey. It is named after the Merck family, which set up Merck Group in Germany in 1668.

Visit Website →

Perrigo Company PLC

HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · USA

Perrigo Company plc is an American Irish registered manufacturer of private label over-the-counter pharmaceuticals.

Visit Website →

Want to dig deeper into these stocks?